World Drug Revenues for Treating Inflammatory Bowel Diseases Will Reach $6.9bn in 2015

Wednesday 2 March 2016, Amsterdam

A new report, now available on ASDReports, a London-based business information company, predicts that world drug revenues for treating inflammatory bowel diseases will reach $6.9bn in 2015. The IBD drug market generated revenues of $5bn in 2010, according to Inflammatory Bowel Diseases: World Drug Market 2011-2021, published in July 2011.

Inflammatory bowel diseases (IBD) are autoimmune disorders in which parts of the intestinal tract experience severe and chronic inflammation. The main forms are Crohn's disease and ulcerative colitis. Inflammatory bowel diseases damage the bowel irreversibly, causing serious discomfort and difficulties for patients. Surgery and drugs have improved patients' lives.

Diya Lahiri, pharmaceutical industry analyst, said: "The world IBD treatments market will benefit from the entry of new technologies, products and companies this decade. There are prominent needs in the IBD treatment market, the most important being the development of drugs that are disease modifying rather than only symptom managing. R&D efforts will help develop novel treatments that will not only benefit patients but also help researchers better understand IBD."